Tonix Pharmaceuticals (NASDAQ:TNXP) vs. Arvinas (NASDAQ:ARVN) Head-To-Head Comparison

Tonix Pharmaceuticals (NASDAQ:TNXPGet Rating) and Arvinas (NASDAQ:ARVNGet Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Institutional & Insider Ownership

22.9% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of Arvinas shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Tonix Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Tonix Pharmaceuticals and Arvinas, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals 0 0 2 0 3.00
Arvinas 0 2 16 0 2.89

Tonix Pharmaceuticals currently has a consensus price target of $41.60, indicating a potential upside of 2,250.28%. Arvinas has a consensus price target of $100.31, indicating a potential upside of 161.57%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Arvinas.

Profitability

This table compares Tonix Pharmaceuticals and Arvinas’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals N/A -48.46% -45.16%
Arvinas -326.72% -29.38% -16.05%

Valuation and Earnings

This table compares Tonix Pharmaceuticals and Arvinas’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tonix Pharmaceuticals N/A N/A -$92.29 million ($7.67) -0.23
Arvinas $46.70 million 43.66 -$191.00 million ($4.17) -9.20

Tonix Pharmaceuticals has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arvinas beats Tonix Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Tonix Pharmaceuticals Company Profile (Get Rating)

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Arvinas Company Profile (Get Rating)

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Want More Great Investing Ideas?

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.